Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:

• Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?

• Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?

• How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?